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REPORT
Human microRNA-155 on Chromosome 21 Differentially Interacts
with Its Polymorphic Target in the AGTR1 3′ Untranslated
Region: A Mechanism for Functional Single-Nucleotide
Polymorphisms Related to Phenotypes
Praveen Sethupathy,* Christelle Borel,* Maryline Gagnebin, Gregory R. Grant, Samuel Deutsch,
Terry S. Elton, Artemis G. Hatzigeorgiou,† and Stylianos E. Antonarakis
Animal microRNAs (miRNAs) regulate gene expression through base pairing to their targets within the 3′ untranslated
region (UTR) of protein-coding genes. Single-nucleotide polymorphisms (SNPs) located within such target sites can affect
miRNA regulation. We mapped annotated SNPs onto a collection of experimentally supported human miRNA targets.
Of the 143 experimentally supported human target sites, 9 contain 12 SNPs. We further experimentally investigated one
of these target sites for hsa-miR-155, within the 3′ UTR of the human AGTR1 gene that contains SNP rs5186. Using
reporter silencing assays, we show that hsa-miR-155 down-regulates the expression of only the 1166A, and not the 1166C,
allele of rs5186. Remarkably, the 1166C allele has been associated with hypertension in many studies. Thus, the 1166C
allele may be functionally associated with hypertension by abrogating regulation by hsa-miR-155, thereby elevating
AGTR1 levels. Since hsa-miR-155 is on chromosome 21, we hypothesize that the observed lower blood pressure in trisomy
21 is partially caused by the overexpression of hsa-miR-155 leading to allele-speciﬁc underexpression of AGTR1. Indeed,
we have shown in ﬁbroblasts from monozygotic twins discordant for trisomy 21 that levels of AGTR1 protein are lower
in trisomy 21.
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MicroRNAs (miRNAs) are ∼21-nt small RNAs involved
in posttranscriptional gene regulation. They have been
shown to guide the RNA-induced silencing complex of
proteins to speciﬁc target sites within mRNAs to induce
immediate cleavage, localization to P-bodies, or transla-
tional repression.1 These target sites are thought to bemost
prevalent in the 3′ UTR of mRNAs.1
SNPs are DNA sequence variations that occur at a rate
of ∼1 in every 1,000 bp in the human genome. SNPs that
occur in the 3′ UTR can affect gene regulation by inter-
fering with posttranscriptional activity, such as protein
binding, polyadenylation, and miRNA binding. Two re-
cent studies reported SNPs that alter the gene expression
level by modifying miRNA targeting activity.2,3 The ﬁrst
showed that a 3′-UTR SNP in human SLITRK1 strengthens
an existing miR-189 target site, thereby amplifying the
down-regulation of SLITRK1, which is implicated in Tour-
ette syndrome.2 The second demonstrated that a 3′-UTR
SNP in the sheep Gdf8 gene creates a new illegitimate
miRNA target site, which leads to signiﬁcant down-regu-
lation of Gdf8 and contributes to muscular hypertrophy.3
miRNA target sites can be categorized into two classes:
5′-dominant and 3′-compensatory. 5′-dominant target sites
have perfect base pairing with at least 7 nt at the 5′ end
of the miRNA, which is also referred to as the “seed” or
“nucleus.”4,5 Such binding is considered in most cases to
be sufﬁcient for a functional miRNA-mRNA interaction.4,5
3′-compensatory target sites are characterized by either a
!7-nt stretch of perfect base pairing or an imperfect 7-nt
base pairing with the miRNA 5′ end, followed by an ex-
tended base pairing with the miRNA 3′ end.6–9 There are
currently three published data sets that provide amapping
of all known SNPs onto a set of computationally predicted
miRNA target sites.3,10,11 Since the introduction of com-
putational miRNA target–prediction programs in 2003,
signiﬁcant progress has been made in the ﬁeld.12,13 How-
ever, current algorithms still simulate only a limited part
of all the biochemical processes that are responsible for a
functional miRNA-mRNA interaction. As a consequence,
such algorithms often lack speciﬁcity.12 Therefore,we limit
our study to experimentally supported target sites.
An up-to-date and comprehensive collection of exper-
imentally supported miRNA target sites can be found in
TarBase 4.0, a manually curated database that includes
1600 miRNA–target gene interactions in eight different
species.14 For each supported miRNA target site, the da-
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tabase describes the location within the 3′ UTR where it
occurs, the nature of the experiments that were conducted
to validate it, and the sufﬁciency of the site to induce
translational repression and/or cleavage. Version 4.0 of
TarBase contains 143 experimentally supported human
target sites for which the exact genomic location is known.
We mapped the human SNPs from dbSNP build 127
onto the experimentally supported human miRNA target
sites mentioned above. This mapping revealed nine hu-
man target sites that harbor 12 SNPs (ﬁg. 1). A recently
published study employing a similar approach also re-
ports one of these target sites (EZH2).11 For three genes
(KCNH2, CAT-1, and ESR1), the target sites are of the 3′-
compensatory class, and, for six genes (AGTR1, EZH2,
HOXA7, SMAD1, DLL1, and GJA1), they are of the 5′-dom-
inant class. Two of the latter six, AGTR1 and EZH2, harbor
SNPs that occur in a region that interrupts 5′-dominant
base pairing. The AGTR1 target site harbors three SNPs,
one of which, rs5186 (1166A/C), is located in the region
that interacts with the miR-155 seed and is also reported
in the Allele Frequency Database (ALFRED). Because the
1166C allele interrupts the interaction with the miR-155
seed (ﬁg. 1), we hypothesized that it may severely impair
miR-155 targeting.
To validate our hypothesis, we proceeded with in vitro
experiments. TarBase shows that this target site gained
experimental support via reporter-silencing assays. More
speciﬁcally, Martin et al. showed that miR-155 represses
AGTR1 in lung ﬁbroblasts via speciﬁc binding to this site.15
We inserted three different AGTR1 3′ UTRs downstream
of luciferase reporter genes to create three distinct reporter
gene constructs: (1) full-length AGTR1 3′ UTR with the
major allele (1166A), (2) full-length AGTR1 3′ UTR with
theminor allele (1166C), and (3) full-lengthAGTR1 3′UTR
with the miR-155 target site deleted. The AGTR1 3′ UTR
with the 1166A allele was ampliﬁed by PCR with use of
sense (5′-CATGTTCGAAACCTGTCCATAAAG-3′) and an-
tisense (5′-ATAAAATTATTTTATTTTAAAGTAAAT-3′) prim-
ers. The PCR products were inserted at the XbaI site in the
3′ UTR of the luciferase gene of the pTAL-Luc vector (Pro-
mega). The pTAL-Luc AGTR1 3′ UTR with the 1166C allele
was constructed similarly with genomic DNA containing
the polymorphic AGTR1 1166C allele. Finally, the pTal-
Luc AGTR1 deletion 1163–1169 construct was generated
using the Quickchange XL site-directed mutagenesis kit
(Stratagene), with use of a forward mutagenic deletion
primer (5′-TCTGCAGCACTTCACTACCAAATGGCTACT-
TTTCAGAATTGAAGG-3′) and a complementary reverse
mutagenic deletion primer (5′-CCTTCAATTCTGAAAAGT-
AGCCATTTGGTAGTGAAGTGCTGCAGA-3′).
293T cells were seeded in 96-well plates (104 cells/well)
in Dulbecco’s modiﬁed Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum. 293T cells were then
transfected with pTAL-Luc AGTR1 3′ UTR A1166/C1166/
deletion 1163–1169 (800 ng), pRL-SV40 Renilla (40 ng
[Promega]), and 2.5 nM, 10 nM, and 20 nM of miR-155
precursor or 20 nM of miR-Let7c as control (double-
stranded RNA oligonucleotide [Ambion]) with the use of
Lipofectamine 2000 (Invitrogen), in accordance with the
manufacturer’s protocol. After 48 h, ﬁreﬂy and Renilla lu-
ciferase activities were measured using a dual luciferase
assay (Promega). The relative reporter activity was ob-
tained by normalization to the Renilla activity.
In the presence of miR-155, the expression of the lu-
ciferase containing the 1166A allele is signiﬁcantly re-
duced (ﬁg. 2), conﬁrming the function of miR-155 on the
AGTR1 target gene. In contrast, the expression of the lu-
ciferase containing the 1166C allele remains unchanged
in the presence or absence of miR-155 (ﬁg. 2). Further-
more, this result is similar to that obtained with the DmiR-
155 target-site luciferase construct, implying that the
1166C allele abolishes the target site and impairs the abil-
ity of miR-155 binding, thereby elevating the levels of
AGTR1. When we repeated the same experiments with a
higher (20 nM) and lower (2.5 nM) amount of miR-155,
the observation did not change (ﬁg. 2).
Hsa-miR-155 maps onto human chromosome 21 and
therefore is triplicated in trisomy 21. Remarkably, it has
been reported that individuals with trisomy 21 have lower
levels of diastolic and systolic blood pressure than do age-
and sex-matched control individuals.16,17 We hypothesize
that overexpression of miR-155 in trisomy 21 excessively
suppresses the AGTR1 common alleles and that this may
be one mechanism contributing to the lower blood pres-
sure in individuals with trisomy 21.
To evaluate the expression of miR-155 in trisomy 21,
we performed real-time quantitative PCR in ﬁbroblasts
from an MZ twin pair discordant for trisomy 21— that is,
one twin was unaffected, and the other had a trisomy 21.
Both twins were homozygotes for the 1166AAGTR1 allele,
which is the target of miR-155. Twins were chosen so that
any gene-expression differences could be attributed only
to the supernumerary chromosome 21 and not to poly-
morphic variability in the rest of the genome. Fibroblast
cells from these MZ twins were grown in DMEM with
Glutamax I medium (Invitrogen) supplemented with 10%
fetal calf serum and 1% penicillin and streptomycin mix
(Invitrogen). Total RNA was extracted by Trizol reagent
(Invitrogen). RNA quality was assessed using an Agilent
2100 BioAnalyzer with the RNA 6000 Nano LabChip.
miRNA expression levels were detected by the SYBR Green
I real-time PCR miRNA detection kit (mirvana [Ambion]),
with the use of SuperTaq (Enzyme Technologies). Reac-
tions were set up, by use of a Biomek 2000 robot (Beck-
man), in a 10-ml volume in 384-well plates. Each RNA
sample was analyzed in six technical replicates and in
three independent experiments, with the use of primer
sets speciﬁc for miR-155 and four different miRNAs used
for normalization: miR-124, miR-130b, miR-24, and miR-
26a. PCRs were run in an ABI 7900 Sequence Detection
System (SDS [Applied Biosystems]).
Raw cycle-threshold (CT) values were obtained using SDS
2.0 software (Applied Biosystems). From the six replicates,
values outside the median0.5 were classiﬁed as outliers
Figure 1. Nine experimentally supported miRNA target sites harbor 12 SNPs. The studies that reported the nine miRNA-target inter-
actions shown here used one or more of the several publicly available computational target-prediction programs to compute the putative
binding diagrams. Seven of the nine SNPs (rs8179014, rs17500932, rs41269629, rs17860720, rs11416, rs5185, and rs12721277) occur
in a region of a 5′-dominant target site that does not affect 5′-dominant base pairing. Three SNPs (rs11541536, rs9579381, and
rs9341070) occur in a region of a 3′-compensatory target site that can affect 3′-compensatory base pairing. Two SNPs (rs5186 and
rs8829) occur in a region of a 5′-dominant target site that does affect 5′-dominant base pairing.
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Figure 2. Effects of miR-155 on the luciferase reporter genes bearing 3′ UTR segments from hAGTR1 3′-UTR. 293T cells were cotransfected
with pTAL-Luc hAGTR1 3′-UTR 1166A or pTAL-Luc hAGTR1 3′ UTR 1166C, pTAL-Luc hAGTR1 3′ UTR deletion 1163–1169, and different
concentrations (20, 10, or 2.5 nM) of miR-155 (white bars) or no miRNA (black bars) or 20 nM of Let-7c (unrelated miRNA [dashed
lines]). Values are means of ﬁreﬂy/Renilla ratio from three independent experiments (each with three culture replicates). Error bars
indicate 1 SD of three independent experiments. P values were calculated from a two-sided, two-sample t test.
Figure 3. Real-time quantitative PCR for mature miR-155 ex-
pression in ﬁbroblast cells from MZ twins discordant for trisomy
21. Data are means (SD) from three independent experiments
analyzed in six replicates. Data are normalized with reference
microRNAs, as mentioned in the text. P values were calculated
from a two-sided, one-sample t test.
and were excluded. For all calculations, CT values were
converted to quantity (q) with the formula . TheCTqp 2
relative expression level of mature miRNAs was normal-
ized according to geNorm,18 with the use of miR-124,miR-
130b, miR-24, and miR-26a as references to determine the
normalization factor. Each miRNA was then mean nor-
malized across the two individuals. Normalized relative
expression values thus have a median of 1. The results
shown in ﬁgure 3 indicate that miR-155 is indeed signif-
icantly overexpressed in ﬁbroblasts of individuals with
trisomy 21. miR-155 is conserved in mouse, and it maps
within the region of mouse chromosome 16 that is trip-
licated in the TS65Dn partial mouse model of Down syn-
drome.19,20 However, this and other such mouse models
could not be used to test the hypothesis, because the miR-
155 target sequence in mouse AGTR1 is not conserved,
and, thus, it is not expected that mmu-miR-155 interacts
with mouse AGTR1.
The increased levels of miR-155 expression in trisomy
21 predict that the AGTR1 protein levels in ﬁbroblasts
isolated from the MZ twins discordant for trisomy 21
should be lower in the twin with trisomy 21 than in the
unaffected euploid twin. Since commercially available
AGTR1 antibodies are not reliable, we performed whole-
cell AGTR1 binding assays as described elsewhere.15 In
brief, the ﬁbroblasts were allowed to reach conﬂuence, the
cell medium was aspirated and was replaced with mon-
oiodinated 125I-[Sar1,Ile8] AngII (2–3#105 cpm [Peptide
Radioiodination Service]) in Hank’s Balanced Salt Solu-
tion, 20 mM Hepes, and 0.1% BSA). After incubation at
room temperature for 60 min, unbound ligand was re-
moved by washing each well twice with 1 ml ice-cold PBS.
Bound ligand was recovered by dissolving the protein in
each well with 1 ml 0.5-M NaOH and 0.01% SDS. Non-
speciﬁc binding was determined by performing the bind-
ing assay in the presence of 1 mM unlabeled AngII. The
quantity of 125I-[Sar1,Ile8] AngII present in each sample
was determined using a Cobra g-spectrophotometer (Pack-
ard Bell). Protein content in wells was assessed using the
BioRad Protein Assay dye reagent (BioRad). Values shown
in ﬁgure 4 represent speciﬁc (total minus nonspeciﬁc)
binding. Consistent with the prediction, the trisomy 21
ﬁbroblasts showed reduced protein levels of AGTR1 com-
pared with that of the euploid ﬁbroblasts (∼30% less;
).P ! .01
ALFRED reports that the minor allele, 1166C, occurs
with much higher frequency in white populations (20%–
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Figure 4. AGTR1 radioligand binding studies in ﬁbroblasts from
MZ twins discordant for trisomy 21. There is a lower amount of
AGTR1 protein in trisomy 21 ﬁbroblasts than in the unaffected
euploid twin ﬁbroblasts.
Figure 5. Model for molecular mechanism of 1166C association with hypertension. The 1166C allele in the 3′ UTR of AGTR1 abrogates
miR-155 binding, which induces elevated levels of AGTR1.
30%) compared with African or Asian populations (5%–
6%). We performed a literature search and identiﬁed 40
studies that investigated the association of the 1166C al-
lele with hypertension (MIM 145500) in various popula-
tions (table A1). Of these studies, 18 reported that 1166C
is a risk allele for hypertension. Type I error, ethnic ad-
mixture, and linkage disequilibrium (LD) are highly un-
likely to explain the large number of studies with positive
ﬁndings (table A1). Furthermore, the discrepancies be-
tween studies are usually greatly decreased in subpopu-
lations deﬁned by ethnic origin—for example, all six stud-
ies with Japanese subjects failed to ﬁnd signiﬁcant as-
sociation, whereas 9 of 13 studies with white subjects
showed signiﬁcant association. Hirschhorn et al. indicate
gene-environment factors as a likely source of variable re-
sults, and this could play a signiﬁcant role in this case,
since there is a strong ethnic bias in the studies with pos-
itive ﬁndings.60 Therefore, although the results must be
interpreted as a function of age, sex, and ethnic origin,
the literature clearly indicates an association of the 1166C
allele with hypertension in several populations.
Despite this literature evidence, the molecular mech-
anism of the association has remained uncertain. Inter-
estingly, it has been independently shown that elevated
levels of AGTR1 contribute to cardiovascular disease.61–63
Accordingly, antagonists of AGTR1 have been developed
and are now widely used in the treatment of hyperten-
sion.64 This suggests that at least one compelling mecha-
nism for the association of 1166C with cardiovascular dis-
ease is the abrogation of miR-155 binding, which elevates
AGTR1 levels (ﬁg. 5). According to expression studies, two
human organs—the spleen and kidney—concomitantly
express AGTR1 and miR-155. Since the kidney is a critical
organ for the regulation of blood pressure, we postulate
that the abrogation of miR-155 binding to AGTR1 is most
detrimental in the kidney. We note here that the mouse
and rat genomes preserve only one of either miR-155 or
its AGTR1 target site. Therefore, rodents are not useful
model organisms for this study.
A recent study provided convincing evidence that
miRNA target sites are under negative selective pressure
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to harbor SNPs.10 These studies include the ∼450 experi-
mentally veriﬁed human miRNAs in the miRBase da-
tabase.65 The number of miRNAs in miRBase has grown
exponentially during the past few years, and there is little
expectation that this growth is complete. A recent mas-
sively parallel sequencing effort identiﬁed 447 novel
miRNAs, many of which are primate speciﬁc.66 Further-
more, current computational/experimental studies con-
jecture that there are at least 1,000 functional miRNAs
encoded within the human genome.67,68 Further charac-
terization of these miRNAs and improvement of target-
prediction programs to enable the speciﬁc prediction of
nonconserved target sites will be critical for a more com-
plete analysis of SNP abundance in miRNA target sites.
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Appendix A
Literature Review
Of the 40 studies we examined in the literature, 18 had
positive results and 22 had negative results. Discrepancies
among the study results are greatly reduced in subpopu-
lations deﬁned by ethnic origin. Each study used a 5%
signiﬁcance level for type I error in the association tests.
Therefore, on the basis of statistical error, we would ex-
pect, on average, only two false-positive associations
among 40 studies. However, given 18 positive associations
among 40 studies, the type I error alone cannot explain
the discrepancy in the results, barring the unlikely pos-
sibility that there are hundreds of negative associations
that have not been published. Furthermore, the discrep-
ancy is usually greatly decreased in subpopulations de-
ﬁned by ethnic origin—for example, all six studies with
Japanese subjects failed to ﬁnd signiﬁcant association,
whereas 9 of 13 studies with white subjects showed sig-
niﬁcant association. Some studies on other non–ethni-
cally deﬁned subpopulations also produced more consis-
tent results. For example, the three studies on preg-
nancy-induced hypertension all found signiﬁcant associ-
ation. It must be noted that some studies that used the
same population type produced inconsistent results. For
example, Reich et al.27 found association in males but not
in females; meanwhile, Tiret et al.57 found association in
females but not in males. Such discrepancies are not sur-
prising in association testing, which is highlighted by the
fact that the Hirschhorn et al.60 review found that only 6
of 166 associations that had been studied at least three
times were positive 175% of the time.
The work of Hirschhorn et al.60 lists the two factors that
can result in false-positive associations as ethnic admix-
ture and LD. Ethnic admixture is unlikely to cause the
observed high number of positive associations, because
the studies comprised a large number of diverse popula-
tions. Furthermore, not all studies with positive results
used the case-control design that is susceptible to strati-
ﬁcation—for example, Kainulainen et al.59 used a family-
based study resulting in a highly signiﬁcant association.
LD can result if the subjects tend to descend from a recent
common ancestor. However, most of the studies used pop-
ulations that were sufﬁciently heterogeneous to avoid this
issue, and, furthermore, no markers have been found in
any of the studies to be in LD with the A1166C poly-
morphism. Therefore, LD is unlikely to explain the large
number of positive results. Hirschhorn et al.60 indicate
gene-environment factors as a likely source of variable re-
sults, and this could play a signiﬁcant role in our case,
since there is a strong ethnic bias in the positive studies.
Therefore, any association of rs5186 with cardiovascular
risk must be interpreted as a function of population—in
particular, age, sex, and ethnic origin.
Hirschhorn et al.60 also discuss the likelihood of obtain-
ing false-negative results when the genetic effect is rela-
tively weak and there is a lack of power in the study to
detect it. Given that the association is real, this is likely
the cause of some of the observed false-negative results,
because the A1166C polymorphism has a fairly low allele
frequency in the population (∼10% to ∼20% in the 40
studies considered). Moreover, when an association is
found, it is not at an extreme level in any case—for ex-
ample, an allele frequency of 28% versus 16% in cases
versus controls in the work of Kainulainen et al.59 Indeed,
a number of the studies found positive trends or P values
that are on the threshold of signiﬁcance. Therefore, we
conclude that the literature provides a very strong case
for a true association of the A1166C polymorphism and
hypertension in several major subpopulations.
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Table A1. Results of 40 Studies that Tested the Association of AGTR1 1166C with Hypertension
Study Association
Ono et al.21 None in Japanese
Takami et al.22 None in Japanese
Sugimoto et al.23 None in Japanese
Kato et al.24 None in Japanese
Katsuya et al.25 None in elderly Japanese
Bonnardeaux et al.26 In whites
Reich et al.27 In white males
Castellano et al.28 In Italians with “clinical” but not “ambulatory” blood pressure and homozygosity
Schmidt et al.29 None in whites
Thomas et al.30 None in Chinese
Thomas et al.31 None in Chinese
Zhu et al.32 In Chinese
Barbalic et al.33 None in Croatians
Kaidashev et al.34 In Ukrainians
Zhang et al.35 None in Chinese (Han)
Spiering et al.36 None in whites
Abdollahi et al.37 None
Henskens et al.38 Association
Gardier et al.39 None
Kobashi et al.40 With pregnancy hypertension
Agachan et al.41 In Turks
Liu et al.42 In Tibetans but not in Han or Yi
Porto et al.43 None with young-onset hypertension
Petrovic et al.44 None with young-onset hypertension
Stankovic et al.45 In Serbian males but not in females
Hindorff et al.46 In whites but not in large white and black mixed study sample
Jiang et al.47 In Chinese (Han)
Giner et al.48 None in Spanish
Dzida et al.49 In Polish
Davis et al.50 None
Li et al.51 None in Chinese
Xiang et al.52 None in Chinese
Nalogowska et al.53 With pregnancy hypertension
Seremak-Mrozikiewicz et al.54 With pregnancy hypertension in Polish
Liyou et al.55 None in Australian elderly
Berge et al.56 Trend seen in three Norwegian populations but not to level of statistical signiﬁcance
Tiret et al.57 In French females but not in males
Wang et al.58 In whites
Kainulainen et al.59 In Finns
Web Resources
The URLs for data presented herein are as follows:
ALFRED, http://alfred.med.yale.edu/alfred/
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for hypertension)
TarBase, http://diana.pcbi.upenn.edu/tarbase (for the database of
experimentally supported targets)
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